IP Verse

Syringe - EP3679922

The patent EP3679922 was granted to Novartis on Oct 8, 2025. The application was originally filed on May 30, 2013 under application number EP20156274A. The patent is currently recorded with a legal status of "Patent Maintained As Amended".

EP3679922

NOVARTIS
Application Number
EP20156274A
Filing Date
May 30, 2013
Status
Patent Maintained As Amended
Sep 5, 2025
Grant Date
Oct 8, 2025
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (4)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

TEVA PHARMACEUTICALSApr 28, 2023ELKINGTON AND FIFEINTERVENTION WITHDRAWN
HAMM & WITTKOPPApr 28, 2022HAMM & WITTKOPPWITHDRAWN
WESSApr 28, 2022SSM SANDMAIRWITHDRAWN
KEIL & SCHAAFHAUSEN PATENTANWALTE PARTGMBBApr 26, 2022KEIL & SCHAAFHAUSEN PATENTANWALTE PARTGMBBWITHDRAWN

Patent Citations (38) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
OPPOSITIONEP0738517
OPPOSITIONEP2047877
OPPOSITIONEP2298392
OPPOSITIONEP2682145
OPPOSITIONEP3536310
OPPOSITIONJP2001340455
OPPOSITIONJP2002177388
OPPOSITIONJP2004313369
OPPOSITIONJP2012045046
OPPOSITIONJPH0725953
OPPOSITIONUS2009247957
OPPOSITIONUS2012078224
OPPOSITIONUS4946441
OPPOSITIONUS5405326
OPPOSITIONUS5597530
OPPOSITIONUS5607399
OPPOSITIONUS5607400
OPPOSITIONUS5667495
OPPOSITIONUS5688252
OPPOSITIONUS7060269
OPPOSITIONUS7678078
OPPOSITIONUS8075535
OPPOSITIONWO2006047325
OPPOSITIONWO2007035621
OPPOSITIONWO2011006877
OPPOSITIONWO2013178771
OPPOSITIONWO2014005728
OPPOSITIONWO9955402
OTHERWO2004091700
OTHERWO2006047325
SEARCHDE102008005938
SEARCHEP1488818
SEARCHEP2298392
SEARCHUS2006293270
SEARCHUS4946441
SEARCHUS8075535
SEARCHWO2007035621
SEARCHWO2011006877

Non-Patent Literature (NPL) Citations (18) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
OPPOSITION- Andrea Wagner, "Advances in Prefilled Syringe Technology", URL: http://www.iptonline.com/articles/public/ipt_24_p73nonprint.pdf, (20171121), XP055427527-
OPPOSITION- Anonymous, "COMPONENTS FOR PREFILLED SYRINGES", DATWYLER, (20111001), DATWYLER, (20240130), XP093125535-
OPPOSITION- Anonymous, "Division of Transplant and Ophthalmology Products Advisory Committee Meeting Briefing Package for Aflibercept injection for the treatment of Patients with neovascular (wet) age-related macular degeration (AMD)", Division of Transplant and Ophthalmology Products Advisory Committee Meeting, pages 1 - 70-
OPPOSITION- Anonymous, "Fachinformation Novartis Pharma Lucentis®", Lucentis®, (20070100), pages 1 - 5, XP055889817-
OPPOSITION- Anonymous, "HIGHLIGHTS OF PRESCRIBING INFORMATION- LUCENTIS® (ranibizumab injection)", Genentech, Inc., (20060601), pages 5 - 11, XP055895380-
OPPOSITION- Anonymous, "HIGHLIGHTS OF PRESCRIBING INFORMATION- LUCENTIS® (ranibizumab injection)", Genentech, Inc., (20100601), pages 5 - 11, XP055895380-
OPPOSITION- Anonymous, "HIGHLIGHTS OF PRESCRIBING INFORMATION - MACUGEN® (pegaptanib sodium injection)", Gilead Sciences, Inc., (20110701), pages 3 - 12, XP055895383-
OPPOSITION- Anonymous, "ISO 11040-5:2007 : Prefilled syringes -- Part 5: Plungers for injectables", (20011215), pages 1 - 10, XP093063217-
OPPOSITION- Anonymous, "MATERIAL SAFETY DATA SHEET- Lucentis®", Genentech Inc., (20090522), pages 1 - 5, XP055895377-
OPPOSITION- Anonymous, "Prefilled syringes Part 4: Glass barrels for injectables Seringues préremplies ", ISO 11040-4, (20070101), pages 1 - 16, XP093003655-
OPPOSITION- Anonymous, "Technical drawing of FluroTec plunger (art. 2342) of West Pharma (2010)", West Pharma, (20100101), West Pharma, (20240130), XP093125537-
OPPOSITION- D64 - Ranibizumab search, EMA-
OPPOSITION- D65 - Grounds for the Decision on EP2869813-
OPPOSITION- D66 - Auxiliary Request 4-
OPPOSITION- D68 - Statement of Juergen Sigg-
OPPOSITION- SCHOENKNECHT T.P. ET AL, "REQUIREMENTS ON PRE-FILLABLE GLASS SYRINGES", AAPS NATIONAL BIOTECHNOLOGY CONFERENCE, (20070627), page 1, XP003035654-
OPPOSITION- T. P. SCHOENKNECHT, "Requirements on pre-fillable glass syringes", AAPS National Biotechnology Conference 2007, (20070000), page 1, XP003035654-
OTHER- FDA, "LUCENTIS® (ranibizumab injection)", HIGHLIGHTS OF PRESCRIBING INFORMATION, (201006), XP002660192-

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents